Main content from here
Dr. Hiromichi Kimura is a co-founder and CEO of Fast Track Initiative, Inc. He is also the founder and CEO of Life Science Management, Inc. and Professor of the Pharmaco-Business Innovation Course at the Graduate School of Pharmaceutical Sciences, the University of Tokyo.
After receiving Ph.D. in pharmaceutical sciences from the University of Tokyo in 1979, Dr. Kimura joined the pharmaceutical division of Kyowa Hakko Kogyo in Tokyo as a product manager with responsibilities including the management of clinical trials and new drug approval applications to the Japanese government. As a company-sponsored student from Kyowa Hakko Kogyo, he attended the Graduate School of Business at Stanford University, where he received an MBA in general management and international business. After returning to Japan in 1985, he became a project Manager responsible for licensing and strategic alliances with foreign pharmaceutical and biotechnology companies.
In 1986 he joined J.P. Morgan as Vice President, Financial Advisory and Mergers & Acquisitions Division, Tokyo and New York (1986-1989) with responsibility for the execution and marketing of cross-border M&A transactions in the pharmaceutical, high-tech and chemical industries. He also conducted industry analysis within the pharmaceutical sector.
He joined Pharmacia K.K. in 1989 as deputy president, board member and head of the Biotechnology Division, becoming President and Representative Director of Pharmacia Biotech K.K. in 1993, and of Amersham Pharmacia Biotech K.K. in 1997. During this time he was also a Board Member of Pharmacia Biotech Asia Pacific Ltd., Hong Kong (1995-1997) and a part-time professor within the Graduate School of Pharmaceutical Sciences at the University of Kyushu, Japan (1994-1998). In the recent past he served as President and Representative Director of Monsanto Japan Ltd. (1998-2000) and as CEO of HuBit Genomix Inc. (2000-2002).
Aside from his academic and business interests, he is trustee of Keizai Doyukai (Japan Association of Corporate Executives) and also serving for Stanford Alumni Association Japan as Deputy Chairman.
Dr. Anzai worked as an Analyst at Arthur D. Little (Japan) Inc., serving biotech, diagnostics and healthcare companies across a range of areas including corporate strategy and new business development. During his professional career as a management consultant at ADL, Dr. Anzai was a member of the Global Healthcare Practice covering pharmaceuticals, IVD, Bio-tech, Med-Tech, Functional Food, and Bio-venture companies.
Prior to joining ADL, Mr. Anzai studied life science in the doctoral course of the University of Tokyo and received his Ph.D. degree in molecular biology from the University of Tokyo, Graduate School of Frontier Sciences in 2004. Dr. Anzai also worked as a special researcher of the Japan Society for the Promotion of Science (JSPS) in the field of molecular biology. In the course of his studies, he published several academic papers.
He is also a Project Associate Professor of Translational Research Initiative in the University of Tokyo. He was also a Visiting Associate Professor of Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University and a part-time lecturer in Faculty of Pharmaceutical Sciences, the University of Tokyo. In 2012, he was serving as a part-time member of Medical Innovation Office, Cabinet Secretariat of the Japanese Government.
Mr. Sato worked at Microsoft Japan Co., Ltd. He joined as head of the healthcare industry in Japan area. He worked at Bayer Yakuhin, Ltd as head of E-marketing of Strategic Business Planning which was established as new department. He implemented multi-channel marketing.
He received his Master of commercial science from the Meiji University, and also work as a special researcher in Social innovation design Laboratory at Meiji University.
Dr. Okuyama started his carrier in pharmaceutical industry as a senior research scientist at Sumitomo pharmaceuticals, now Dainippon Sumitomo pharmaceuticals, one of a Japanese top tier pharmaceutical company, and he joined DNAVEC, a government affiliated joint venture biotech company, focusing on gene therapy. Through the 7 years experiences in industry, he has acquired extensive knowledge in molecular biology, neurology, gene therapy, and lipid metabolism. Prior to re-joining FTI and LSM in Oct. 2013, he has 12 years experience in biotech investment and startup incubation with BHP and FTI/LSM.
He received his Ph. D. in pharmaceutical sciences from the University of Tokyo in 1995
Dr. Kimura worked as a consultant at Sigmaxyz, Inc. (Mitsubishi Corporation Group), serving companies in the field of life science/healthcare, ICT & media etc. across a range of areas including business planning, new business development and alliances/acquisition support for the new business area and overseas expansion.
Prior to joining Sigmaxyz, she studied molecular biology in the master's course and cognitive neuroscience in the doctoral course of the University of Tokyo, then received her Ph.D degree in neuroscience from the University of Tokyo, Graduate School of Medicine.
Ms. Kanazawa began her career with Arthur D. Little (Japan) Inc. in 2005 and worked on wide range of business issues such as R&D strategy, new business development and organizational restructuring. Also, she has experience of hands-on change management and comprehensive marketing at Shinseibank, ltd.
She holds a M.S. from University of Tokyo (life science) and a MBA from IESE business school.
Dr. Hayashida began scientist career at RIKEN in 2004, where he engaged in research related to nucleic acid medicine. He then shifted to the New Business Development department in the private sector where he helped establish new projects, including those related to the research and development of biomaterials and medical equipment from the planning phase to establishment. He subsequently became established as a business development consultant. He also participated in a number of projects under the Central Government Ministries and Agencies. He was commissioned by the Ministry of Economy, Trade and Industry to engage in research of the Japanese economy, as well the development of technology and related systems, in order to explore the adaptive possibilities in developing countries and set up overseas subsidiaries. Since 2015, he has taken an active part in Life Science Management Inc. and Fast Track Initiative, Inc.
He received his Ph.D. of Science from Kyoto University in 2004.Dr Sengoku earned his doctoral degree in science in 2001 from the University of Tokyo.
Dr. Yujiro Maeda is a Project Assistant Professor of Medical Innovation Initiative and Medical Device Development & Regulation Research Center, The University of Tokyo. In 2014 he was certificated to finish global faculty training by Stanford Biodesign, world-class med-tech innovation program in Stanford University. He attended the startiup Stanford Biodesign program in Tokyo in 2015. From 2006 to 2013, He worked as a clinical fellow, Dept. of Oral and Maxillofacial Surgery and Div. of Emergency and Critical Care Medicine, The University of Tokyo Hospital. He is a certificated surgeon, Japanese Society of Oral and Maxillofacial Surgeons. His clinical interests are cleft lips and palate surgery, orthognathic surgery, reconstruction surgery, bone grafting surgery and dental surgery. In 2013, he worked for Division of Global Pharmaceutical Business of Otsuka Pharmaceutical Co.Ltd..
He received Doctor of Dental Surgery from Kyushu University in 2006. He received his Ph.D. of Surgical Medicine from The University of Tokyo(2014).
After graduating pharmaceutical sciences of Tokyo University in 1979, Ms. Fukuda joined Chugai pharmaceutical Co., Ltd. In 2003, she became a Head of Business Intelligence Department with responsibilities including market research, business assessment and portfolio analysis, and worked as a R&D decision-making committee member. She also worked as a senior professional of pharmacovigilance information evaluation, and pricing. Through experiences of more than 30 years in industry, she has acquired extensive knowledge in R&D product life cycle management.
She joined FTI and LSM in September 2015.
She is a certified pharmacist.
Dr Sengoku is an Associate Professor of the Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University and the Principal Investigator of its Innovation Management Group; a Visiting Lecturer of Faculty of Pharmaceutical Sciences, the University of Tokyo; a Director of non-profit organisation Kyoto SMI (Smart Materials for Innovation). He has professional experience in advisory services at McKinsey&Company (2001-05); Fast Track Initiative, Inc. (a venture capital focusing on biotechnology and healthcare industries, 2005-07); Life Science Management (2005-07), and research and education experience in the field of management of technology at the University of Tokyo (2005-07) and International Collaborative Center, Kyoto University (2008-09). He joined WPI-iCeMS in April 2009 and has been leading the Innovation Management Group.
Dr Sengoku earned his doctoral degree in science in 2001 from the University of Tokyo.